These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32421446)

  • 61. Dermatologic toxicities of targeted anticancer therapies.
    Balagula Y; Lacouture ME; Cotliar JA
    J Support Oncol; 2010; 8(4):149-61. PubMed ID: 20822032
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.
    Nikolaou V; Voudouri D; Tsironis G; Charpidou A; Stamoulis G; Triantafyllopoulou I; Panoutsopoulou I; Xidakis E; Bamias A; Samantas E; Aravantinos G; Gogas H; Rigopoulos D; Syrigos K; Stratigos A
    Support Care Cancer; 2019 Dec; 27(12):4535-4542. PubMed ID: 30919155
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hair disorders in patients with cancer.
    Freites-Martinez A; Shapiro J; Goldfarb S; Nangia J; Jimenez JJ; Paus R; Lacouture ME
    J Am Acad Dermatol; 2019 May; 80(5):1179-1196. PubMed ID: 29660422
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapy-Related Toxicity: A Primer for the Radiologist.
    Thomas R; Howard SA; Laferriere SL; Braschi-Amirfarzan M
    AJR Am J Roentgenol; 2020 Sep; 215(3):770-780. PubMed ID: 32755160
    [No Abstract]   [Full Text] [Related]  

  • 66. Supportive care for patients undergoing immunotherapy.
    Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
    Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neurological sequelae of cancer immunotherapies and targeted therapies.
    Wick W; Hertenstein A; Platten M
    Lancet Oncol; 2016 Dec; 17(12):e529-e541. PubMed ID: 27924751
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Side effects of targeted therapies: rash.
    Eaby-Sandy B; Lynch K
    Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nasal vestibulitis due to targeted therapies in cancer patients.
    Ruiz JN; Belum VR; Boers-Doets CB; Kamboj M; Babady NE; Tang YW; Valdez TA; Lacouture ME
    Support Care Cancer; 2015 Aug; 23(8):2391-8. PubMed ID: 25876156
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dermatologic Adverse Events in Oncologic Therapies.
    Čeović R; Kovačec L; Bukvić Mokos Z; Marinović B
    Acta Dermatovenerol Croat; 2022 Dec; 30(4):237-249. PubMed ID: 36919390
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of dermatologic adverse events induced by targeted therapies on quality of life.
    Charles C; Bungener C; Razavi D; Mateus C; Routier E; Lanoy E; Verschoore M; Robert C; Dauchy S
    Crit Rev Oncol Hematol; 2016 May; 101():158-68. PubMed ID: 26995080
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metabolic disorders associated with the use of targeted cancer therapies.
    Kotecki N; Penel N; Awada A
    Curr Opin Oncol; 2015 May; 27(3):258-66. PubMed ID: 25730544
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies.
    Raheem F; Alsuhebany N; Hickey Zacholski E; Paulic N; Sandler A; Uk N; Moore DC
    Expert Opin Drug Saf; 2023; 22(10):921-928. PubMed ID: 37612255
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
    Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
    Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Toxicities of checkpoint inhibitors: causes and management.
    Postow MA
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813
    [No Abstract]   [Full Text] [Related]  

  • 76. Cardiotoxicity Following Cancer Treatment.
    Walls GM; Lyon AR; Harbinson MT; Hanna GG
    Ulster Med J; 2017 Jan; 86(1):3-9. PubMed ID: 28298705
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adverse events of targeted therapies.
    Klastersky JA
    Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combining immunotherapy and targeted therapies in cancer treatment.
    Vanneman M; Dranoff G
    Nat Rev Cancer; 2012 Mar; 12(4):237-51. PubMed ID: 22437869
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Adverse effects of oncohaematological immunotherapy: implications for Primary Care and continuity of care].
    Vidal Lopez C; Ríos Quito GL; Salom Garrigues C; Pellicer Sanahuja AI
    Semergen; 2020; 46(1):60-67. PubMed ID: 31591035
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.